News tagged with erlotinib
'Happy hour' gene discovery suggests cancer drugs might treat alcoholism
A class of drugs already approved as cancer treatments might also help to beat alcohol addiction. That's the conclusion of a discovery in flies of a gene, dubbed happyhour, that has an important and previously unknown role ...
May 21, 2009 |
4.8 / 5 (4) |
1
Patient access schemes for high-cost cancer medicines: Good in theory, difficult in practice
created by the pharmaceutical industry to allow access to expensive cancer drugs—can be fraught with administrative problems, meaning that money does not reach the parts of the UK National Health Service that it should, ...
Jan 31, 2010 |
5 / 5 (1) |
0
Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) ...
Nov 17, 2010 |
5 / 5 (1) |
0
Erlotinib effective and with fewer side-effects after first-line treatment
The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results ...
Feb 26, 2011 |
not rated yet |
0
Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer
Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib.
Feb 25, 2011 |
5 / 5 (1) |
0
New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a ...
Oct 09, 2010 |
not rated yet |
0
TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, revers ...
Oct 01, 2010 |
not rated yet |
0
African-Americans equally likely to benefit from erlotinib and other targeted lung cancer therapy
African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted ...
Sep 28, 2010 |
not rated yet |
0
Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, ...
Oct 12, 2010 |
5 / 5 (1) |
1
Assessing positive outcomes of phase III trials
Randomized phase III studies should be designed to find out whether a new drug or treatment makes a meaningful difference in patients' survival or quality of life, according to a commentary published online December 3rd in ...
Dec 03, 2010 |
not rated yet |
0
Blood test may identify lung cancer patients likely to respond to erlotinib
Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, ...
Apr 30, 2010 |
not rated yet |
0
Erlotinib maintenance therapy prolongs survival in patients with the most common form of lung cancer
Erlotinib maintenance therapy given after platinum-based chemotherapy is well tolerated, significantly improves progression free survival (PFS), and increases overall survival in patients with advanced non-small-cell lung ...
May 19, 2010 |
not rated yet |
0
Economic analysis: Erlotinib marginally cost-effective
Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally ...
Feb 16, 2010 |
not rated yet |
0
Personalized molecular therapy shows promising results for people with advanced lung cancer
A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium ...
Dec 09, 2010 |
not rated yet |
0
Erlotinib
Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche. In lung cancer, it extends life by an average of 3.3 months at a cost of CDN$95,000.
For more information about Erlotinib, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
